243 related articles for article (PubMed ID: 31403542)
1. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
2. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
[TBL] [Abstract][Full Text] [Related]
3. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
5. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
[TBL] [Abstract][Full Text] [Related]
8. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
10. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
[No Abstract] [Full Text] [Related]
11. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
12. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
13. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
14. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
16. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
17. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
Chitnis SD; Seim NB; Kendra K
J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
[TBL] [Abstract][Full Text] [Related]
18. Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response.
Iglesias P; Ribero S; Barreiro A; Podlipnik S; Carrera C; Malvehy J; Puig S
Acta Derm Venereol; 2019 Feb; 99(2):232-233. PubMed ID: 30281140
[No Abstract] [Full Text] [Related]
19. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
20. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
Gupta M; Brennan DC; Alhamad T
Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
[No Abstract] [Full Text] [Related]
[Next] [New Search]